Advanced in Acute Myeloblastic Leukemia without Maturation

Bart Vandekerckhove

Gent, VLG, BE 
Advanced in Acute Myeloblastic Leukemia without Maturation
Gent, VLG, BE 
OverviewLocationsClinical Research

Overview

Bart Vandekerckhove practices in Gent, Belgium. Mr. Vandekerckhove is rated as an Advanced expert by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Wiskott-Aldrich Syndrome, Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, and Intestinal Cancer.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Acute Myeloblastic Leukemia without Maturation.

Gender
Male

Locations

Gent, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase I Study of MIDRIXNEO-LUNG, an Autologous Neoantigen-targeted Dendritic Cell Immunotherapy in Patients With Non-small Cell Lung Cancer
Phase I Study of MIDRIXNEO-LUNG, an Autologous Neoantigen-targeted Dendritic Cell Immunotherapy in Patients With Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Biological
Study Drugs: Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH
Study Phase: Phase 1
Phase Ia Study of MIDRIX4-LUNG, a Tetravalent Autologous Dendritic Cell Vaccine, in Patients With Metastatic Non-small Cell Lung Cancer
Phase Ia Study of MIDRIX4-LUNG, a Tetravalent Autologous Dendritic Cell Vaccine, in Patients With Metastatic Non-small Cell Lung Cancer
Enrollment Status: Unknown
Publish Date: March 30, 2021
Intervention Type: Biological
Study Drugs: Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH
Study Phase: Phase 1
View 1 Less Clinical Trial

79 Total Publications

Ex vivo-generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates.
Ex vivo-generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates.
Journal: Frontiers in immunology
Published: April 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vandekerckhove's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile